The use of SGLT2i in combination with dipeptidyl peptidase-4 inhibitors (DPP4i) with glycemic and extra-glycemic benefits helps to target various pathophysiological pathways in T2DM and provides a distinct advantage, supporting the early implementation of this combination in the management of T2DM [6]. The combination of SGLT2i and DPP4i results in a greater reduction in mean HbA1c (-0.62%) when compared to DPP4i used alone (-0.35%) with significant weight loss seen in the combination vs. DPP4i used alone, but not vs. SGLT2i. Here, DPP4 is linked to type 2 diabetes mellitus.